Zimmer Biomet Holdings, Inc. (ZBH)
| Market Cap | 19.19B +7.6% |
| Revenue (ttm) | 8.57B +7.0% |
| Net Income | 767.40M -4.7% |
| EPS | 3.95 -2.0% |
| Shares Out | 189.25M |
| PE Ratio | 25.66 |
| Forward PE | 11.50 |
| Dividend | $0.96 (0.95%) |
| Ex-Dividend Date | Sep 30, 2026 |
| Volume | 3,135,783 |
| Open | 104.03 |
| Previous Close | 103.21 |
| Day's Range | 99.70 - 104.03 |
| 52-Week Range | 79.12 - 112.55 |
| Beta | 0.47 |
| Analysts | Buy |
| Price Target | 116.90 (+15.28%) |
| Earnings Date | Nov 4, 2026 |
About ZBH
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder; and craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well a... [Read more]
Financial Performance
In 2025, Zimmer Biomet Holdings's revenue was $8.23 billion, an increase of 7.20% compared to the previous year's $7.68 billion. Earnings were $705.10 million, a decrease of -21.98%.
Financial StatementsAnalyst Summary
According to 27 analysts, the average rating for ZBH stock is "Buy." The 12-month stock price target is $116.9, which is an increase of 15.28% from the latest price.
News
Zimmer Biomet price target lowered to $101 from $102 at BMO Capital
BMO Capital lowered the firm’s price target on Zimmer Biomet (ZBH) to $101 from $102 and keeps a Market Perform rating on the shares. The firm is adjusting its model…
Zimmer Biomet price target raised to $140 from $125 at Stifel
Stifel analyst Rick Wise raised the firm’s price target on Zimmer Biomet (ZBH) to $140 from $125 and keeps a Buy rating on the shares.
Zimmer Biomet to Present at the Annual Jefferies Global Healthcare Conference in London
WARSAW, Ind., Nov. 9, 2026 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of the Zimmer Biomet management team will ...
Zimmer Biomet price target raised to $115 from $100 at Barclays
Barclays raised the firm’s price target on Zimmer Biomet (ZBH) to $115 from $100 and keeps an Equal Weight rating on the shares. The company showed encouraging progress excluding knees…
Zimmer Biomet Introduces Surgeon-Guided Autonomy, a New Category in Intelligent Surgery
New Category Will Introduce a Closed-Loop Framework: Predict. Perform. Recover.
Zimmer Biomet price target raised to $114 from $106 at Truist
Truist analyst Richard Newitter raised the firm’s price target on Zimmer Biomet (ZBH) to $114 from $106 and keeps a Hold rating on the shares. Q3 saw another quarter of…
Zimmer Biomet price target raised to $125 from $110 at RBC Capital
RBC Capital raised the firm’s price target on Zimmer Biomet (ZBH) to $125 from $110 and keeps an Outperform rating on the shares. The firm cites the company’s Q3 earnings…
Zimmer Biomet price target raised to $120 from $117 at JPMorgan
JPMorgan analyst Robbie Marcus raised the firm’s price target on Zimmer Biomet (ZBH) to $120 from $117 and keeps a Neutral rating on the shares.
Zimmer Biomet price target raised to $130 from $120 at UBS
UBS raised the firm’s price target on Zimmer Biomet (ZBH) to $130 from $120 and keeps a Buy rating on the shares.
Zimmer Biomet price target raised to $111 from $100 at Canaccord
Canaccord analyst Caitlin Cronin raised the firm’s price target on Zimmer Biomet (ZBH) to $111 from $100 and keeps a Hold rating on the shares. The firm said they delivered…
Zimmer Biomet price target raised to $125 from $110 at Stifel
Stifel raised the firm’s price target on Zimmer Biomet (ZBH) to $125 from $110 and keeps a Buy rating on the shares.
Zimmer Biomet price target raised to $114 from $104 at Baird
Baird raised the firm’s price target on Zimmer Biomet (ZBH) to $114 from $104 and keeps a Neutral rating on the shares. The firm updated its model following Q3 results…
Zimmer Biomet price target raised to $117 from $99 at Citi
Citi raised the firm’s price target on Zimmer Biomet (ZBH) to $117 from $99 and keeps a Neutral rating on the shares.
Zimmer Biomet price target raised to $107 from $93 at Bernstein
Bernstein raised the firm’s price target on Zimmer Biomet (ZBH) to $107 from $93 and keeps a Market Perform rating on the shares. The firm notes the company reported solid…
Zimmer Biomet price target raised to $125 from $110 at RBC Capital
RBC Capital raised the firm’s price target on Zimmer Biomet (ZBH) to $125 from $110 and keeps an Outperform rating on the shares.
These stocks have soared the most today after the Democrats trounced Trump
Stanley Black & Decker's stock was the strongest performer among the S&P 500, while several tech players and associated power providers showed sharp declines.
Zimmer Biomet Holdings Earnings Call Transcript: Q3 2026
Q3 sales grew 3.7% in constant currency, with broad strength across hips, S.E.T., and technology offsetting knee and China headwinds. Full-year sales and adjusted EPS guidance increased, while U.S. commercial investment and Monogram remain key execution priorities.
Zimmer Biomet Holdings Earnings release: Q3 2026
Zimmer Biomet Holdings released its Q3 2026 earnings on November 4, 2026, summarizing the period's financial results.
Zimmer Biomet Holdings Quarterly report: Q3 2026
Zimmer Biomet Holdings has published its Q3 2026 quarterly earnings report on November 4, 2026.
Zimmer Biomet Announces Third Quarter 2026 Financial Results
Third quarter net sales of $2.063 billion increased 3.1% on a reported basis and 3.7% on a constant currency1 basis Third quarter diluted earnings per share were $1.00, a decrease of 13.8%; adjusted1 ...
Zimmer Biomet to Preview the Next Era of Intelligent Orthopedic Surgery at AAHKS 2026
Featured symposium will reveal a new vision for intelligent systems that support surgeon judgment, reduce procedural burden and connect the episode of care WARSAW, Ind., Oct. 29, 2026 /PRNewswire/ -- ...
3 of the Best Smaller-Cap Stocks to Own
These stocks of smaller companies with wide economic moats are good long-term buys when you can get them on sale.
Zimmer Biomet’s recent weakness offers a buying opportunity, says Argus
Argus analyst David Toung keeps a Buy rating and $125 price target on Zimmer Biomet (ZBH) but believes that the stock’s recent weakness offers a buying opportunity. The company has…
Zimmer Biomet and THINK Surgical extend exclusive distribution agreement
Zimmer Biomet (ZBH) and THINK Surgical, a company in the field of orthopedic surgical robots, announced a multi-year extension of its Limited Exclusive Distribution and Supply Agreement following a su...
ZIMMER BIOMET AND THINK SURGICAL EXTEND EXCLUSIVE DISTRIBUTION AGREEMENT
Multi-Year Extension to Help Accelerate Adoption of Wireless, Handheld TMINI® System for Use with Zimmer Biomet's Persona® Knee System FREMONT, Calif. and WARSAW, Ind.